Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Franzoi MA, Agostinetto E, Perachino M, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–e313.
   PubMed Web of Science ®Google Scholar
• Lubián López DM, Butrón Hinojo CA, Sánchez-Prieto M, et al. Sexual dysfunction in postmenopausal women with breast cancer on adjuvant aromatase inhibitor therapy. Breast Care (Basel). 2021;16(4):376–382.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647–3661.
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(17):1673.
   PubMed Web of Science ®Google Scholar
• Dragvoll I, Bofin AM, Søiland H, et al. Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer. BMC Cancer. 2022;22(1):1247.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML. Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American Menopause Society. Climacteric. 2014;17:557–563.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Seracchioli R, Salvatore S, et al. Investigators of the EVES study. impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. 2019;35(5):453–459.
   PubMed Web of Science ®Google Scholar
• Carmen A, Anne O, Monika S, et al. Does the toxicity of endocrine therapy persist into long-term survivorship?: Patient-reported outcome results from a follow-up study beyond a 10-year-survival. Breast Cancer Res Treat. 2022 Nov 23.
   PubMed Web of Science ®Google Scholar
• Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167–173.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799.
   PubMed Web of Science ®Google Scholar
• Lee YK, Chung HH, Kim JW, et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol. 2011;117:922–927.
   PubMed Web of Science ®Google Scholar
• Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012;8(3):144–148.
   PubMedGoogle Scholar
• Mension E, Alonso I, Castelo-Branco C. Genitourinary syndrome of menopause: current treatment options in breast cancer survivors – systematic review. Maturitas. 2021;143:47–58.
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, D’Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17:611–617.
   PubMed Web of Science ®Google Scholar
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29(7):767–794.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martella S, Albani F, et al. Hyaluronic acid: a valid therapeutic option for early management of genitourinary syndrome of menopause in cancer survivors? Healthcare. 2022;10:1528.
   Web of Science ®Google Scholar
• Chen J, Geng L, Song X, et al. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(6):1575–1584.
   PubMed Web of Science ®Google Scholar
• Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387–395.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Anderson H. HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer–is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–455.
   PubMed Web of Science ®Google Scholar
• Management of menopausal symptoms in women with a history of breast cancer. Australia: Cancer Australia. 2016 Dec. [cited 2023 Jan 12].
   Google Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145:371–379.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang L. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy. Pharmacol Res. 2021;166:105509.
   PubMed Web of Science ®Google Scholar
• Le Ray I, Dell’Aniello S, Bonnetain F, et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135:603–609.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Cebrecos I, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric. 2022;25(5):476–482.
   PubMed Web of Science ®Google Scholar
• Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30:429–436.
   PubMed Web of Science ®Google Scholar
• Li FG, Maheux-Lacroix S, Deans R, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA. 2021;326(14):1381–1389.
   PubMed Web of Science ®Google Scholar
• Cruff J, Khandwala S. A double-blind randomized sham-controlled trial to evaluate the efficacy of fractional carbon dioxide laser therapy on genitourinary syndrome of menopause. J Sex Med. 2021;18(4):761–769.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal ’rejuvenation’ or vaginal cosmetic procedures: FDA safety communication. Available from: https://www.fda.gov/medical-devices/safetycommunications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic
   Google Scholar
• Salvatore S, Nappi RE, Casiraghi  A, et al. Microablative fractional CO2 laser for vulvovaginal atrophy in women with a history of breast cancer: a pilot study at 4-week follow-up. Clin Breast Cancer. 2021;21(5):e539–e546.
   PubMed Web of Science ®Google Scholar
• Kendall A, Dowsett M, Folkerd E, et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584–587.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Glatz C, Königsberg R, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric. 2011;14(3):339–344.
   PubMed Web of Science ®Google Scholar
• Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313–319.
   PubMed Web of Science ®Google Scholar
• Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist. 2011;16(4):424–431.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Tortajada M, et al. Vaginal laser therapy for genitourinary syndrome of menopause – systematic review. Maturitas. 2022;156:37–59.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Anglès-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2255697.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18(2):233–240.
   PubMed Web of Science ®Google Scholar
• Lilue M, Palacios S, Del Carmen Pingarrón Santofimia M. Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies. Drugs Context. 2020;9:2020–3-4.
   Google Scholar
• The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020;27(9):976–992.
   PubMed Web of Science ®Google Scholar
• Anglès-Acedo S, Ribera-Torres L, Mension E, et al. Sexual health in breast cancer survivors with genitourinary syndrome of menopause: it is only a dyspareunia issue? J Sexual Med. 2022;19(Suppl 4):S98.
   PubMedGoogle Scholar
• Castillo H, Mension E, Cebrecos I, et al. Sexual function in breast cancer patients: a review of the literature. Clin Exp Obstet Gynecol. 2022;49(6):134.
   Web of Science ®Google Scholar
• Nimbi FM, Magno S, Agostini L, et al. Sexuality in breast cancer survivors: sexual experiences, emotions, and cognitions in a group of women under hormonal therapy. Breast Cancer. 2022;29:419–428.
   PubMed Web of Science ®Google Scholar
• Ros C, Mension E, Rius M, et al. 2023. Assessing the vaginal wall thickness by transvaginal ultrasound in breast cancer survivors: a pilot study. Maturitas. 2023;171:7–12.
   Google Scholar
• Davis SR, Robinson PJ, Jane F, et al. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103:4146–4154.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Tortajada M, et al. Genitourinary syndrome of menopause assessment tools. J Midlife Health. 2021;12(2):99–102.
   PubMedGoogle Scholar
• Bartula I, Sherman KA. The Female Sexual Functioning Index (FSFI): evaluation of acceptability, reliability, and validity in women with breast cancer. Support Care Cancer. 2015;23:2633–2641.
   PubMed Web of Science ®Google Scholar
• Tounkel I, Nalubola S, Schulz A, et al. Sexual health screening for gynecologic and breast cancer survivors: a review and critical analysis of validated screening tools. Sex Med. 2022;10:100498.
   PubMed Web of Science ®Google Scholar